ALISO VIEJO, Calif. May 08, 2024 (NASDAQ: RXST) ’ RxSight, Inc. a leading ophthalmic medical device company specializing in providing personalized vision solutions post cataract surgery, announced today the pricing of its underwritten public offering.The company is planning to sell 1,785,714 shares of its common stock at $56.00 per share to the public.This move is expected to generate gross proceeds of approximately $100.0 million for RxSight, assuming the underwriters’ option to purchase additional shares is not exercised.
The offering is anticipated to close on or around May 13, 2024, subject to the fulfillment of customary closing conditions.BofA Securities is acting as the lead bookrunning manager and representative of the underwriters, while J.P.Morgan is also serving as a bookrunning manager for the offering.BTIG is acting as the co-manager for the transaction.
With the announcement of this public offering, it is clear that RxSight aims to further strengthen its financial position and capitalize on its growth opportunities.This development highlights the company’s robust market presence and its dedication to providing innovative and personalized treatment options to patients experiencing cataract-related vision issues.
This recent move comes on the heels of RxSight’s earlier statement on January 07, 2024, where the company released preliminary unaudited financial and operational results for the fourth quarter and full-year 2023, along with providing guidance for the full-year 2024.This previous announcement shed light on RxSight’s stellar performance and anticipated growth trajectory.
The news about the public offering is expected to have a positive impact on RxSight’s shareholders.The availability of additional capital through the issuance of new shares can enhance the company’s ability to fund its ongoing research and development efforts, expand its market reach, and explore investments in cutting-edge technology.Shareholders may view this as a promising opportunity to strengthen their investment in RxSight and align themselves with a company that is at the forefront of ophthalmic medical device innovations.
As of now, RxSight has 35.662397 million outstanding shares, with a current trading price of $62.19.The pricing of the underwritten public offering at $56.00 per share suggests a potential discount to the current market price.This pricing strategy could incentivize more investors to participate in the offering, further enhancing shareholder value by potentially increasing the overall demand for RxSight’s shares.
In conclusion, RxSight’s priced underwritten public offering represents a strategic move by the company to reinforce its financial standing and fuel its growth trajectory.The strong response from shareholders and potential investors indicates confidence in RxSight’s business model and its ability to provide high-quality, customized vision solutions for patients post cataract surgery.With the additional capital from the public offering, RxSight is well-positioned to continue its mission of revolutionizing ophthalmic medical devices and creating value for its shareholders.
Comments